The status and progress of intravitreal chemotherapy for resistant or recurrent retinoblastoma / 中华眼底病杂志

ABSTRACT

Nowadays,one of the most challenging aspects of retinoblastoma (RB) therapy is how to control the resistant or recurrent viable vitreous seeds,for which intravenous chemotherapy appears to be ineffective.Recently,intravitreal chemotherapy offers another option to control advanced stage and vitreous seeds of RB,and may be a promising new approach to RB therapy.However,intravitreal injection for RB patients raises considerable controversy due to concerns of possible extraocular extension along the injection route,and should not replace the primary standard of care for bilateral RB or group E eyes of RB.Close follow-up and further studies are needed to determine appropriate indications,to determine the effective drugs and concentrations,to optimize RB therapy protocols and to investigate the relationship between long-term efficacy and toxicities.